Literature DB >> 7682158

CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

N Thieblemont1, N Haeffner-Cavaillon, A Ledur, J L'Age-Stehr, H W Ziegler-Heitbrock, M D Kazatchkine.   

Abstract

Peripheral blood and tissue mononuclear phagocytes serve as major viral reservoirs in HIV-infected individuals. We investigated the role of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) in mediating productive infection with complement-opsonized HIV-1 and HIV-2 of cultured normal human peripheral blood monocytes, the promonocytic cell line THP-1, the monocytic cell line Mono Mac 6 and the glial cell line U251-MG. Cells were infected with the HTLV-IIIB strain of HIV-1 or the LAV-2 strain of HIV-2 that had been preopsonized with fresh human normal HIV seronegative serum. Productive infection was assessed by syncytia formation, the MTT cytotoxicity assay and/or release of p24 antigen in culture supernatants. Using suboptimal amounts of virus to infect the cells, we observed a higher and earlier productive infection of the cells with complement-opsonized HIV than with unopsonized virus. The enhancing effect of complement was totally suppressed by blocking CR1 or CR3 function with F(ab)'2 fragments of anti-receptor MoAbs; while blocking of the LFA-1 antigen had no effect. The infection of monocytic cells with complement-opsonized virus occurred independently of CD4 since it was not inhibited by F(ab)'2 fragments of a MoAb against the gp120 binding site of CD4 and since infection also occurred with Mono Mac 6 and U251-MG cells, which lack expression of the CD4 antigen and of CD4 mRNA. These observations suggest that complement may mediate productive infection of cells of the monocytic lineage with 'lymphocytotropic' HIV strains independently of CD4.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682158      PMCID: PMC1554886          DOI: 10.1111/j.1365-2249.1993.tb05955.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation.

Authors:  R A June; S Z Schade; M J Bankowski; M Kuhns; A McNamara; T F Lint; A L Landay; G T Spear
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

2.  Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages.

Authors:  H Schuitemaker; N A Kootstra; M H Koppelman; S M Bruisten; H G Huisman; M Tersmette; F Miedema
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

3.  Functional epitope analysis of the human CD11a/CD18 molecule (LFA-1, lymphocyte function-associated antigen 1) involved in HIV-1-induced syncytium formation.

Authors:  C Vermot-Desroches; D Rigal; S Escaich; J Bernaud; C Pichoud; J P Lamelin; C Trepo
Journal:  Scand J Immunol       Date:  1991-10       Impact factor: 3.487

4.  Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.

Authors:  G S Gras; D Dormont
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Antibodies and complement enhance binding and uptake of HIV-1 by human monocytes.

Authors:  L J Bakker; H S Nottet; N M de Vos; L de Graaf; J A Van Strijp; M R Visser; J Verhoef
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

6.  Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide.

Authors:  J M Harouse; S Bhat; S L Spitalnik; M Laughlin; K Stefano; D H Silberberg; F Gonzalez-Scarano
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

7.  Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120.

Authors:  S Bhat; S L Spitalnik; F Gonzalez-Scarano; D H Silberberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

8.  Isolation of normal human follicular dendritic cells and CD4-independent in vitro infection by human immunodeficiency virus (HIV-1).

Authors:  I Stahmer; J P Zimmer; M Ernst; T Fenner; R Finnern; H Schmitz; H D Flad; J Gerdes
Journal:  Eur J Immunol       Date:  1991-08       Impact factor: 5.532

9.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.

Authors:  V Boyer; C Desgranges; M A Trabaud; E Fischer; M D Kazatchkine
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 3.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

4.  Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Authors:  Isabel Y Pappworth; Christine Hayes; Jason Dimmick; B Paul Morgan; V Michael Holers; Kevin J Marchbank
Journal:  Immunobiology       Date:  2011-06-25       Impact factor: 3.144

5.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

6.  Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin.

Authors:  Gregory T Spear; M Reza Zariffard; Ji Xin; Mohammed Saifuddin
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

7.  Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium.

Authors:  L A Hussain; C G Kelly; A Rodin; M Jourdan; T Lehner
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

8.  Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response.

Authors:  Custodio Bila; Verena Oberhauser; Christoph G Ammann; Asim Ejaz; Georg Huber; Simone Schimmer; Ron Messer; Marcela Pekna; Dorothee von Laer; Ulf Dittmer; Kim J Hasenkrug; Heribert Stoiber; Zoltán Bánki
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

9.  Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

Authors:  R M Welsh; C L O'Donnell; D J Reed; R P Rother
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.